达比加群与金黄色葡萄球菌菌血症风险:全国性队列研究
该研究基于丹麦全国登记数据,纳入112 537例房颤患者,比较达比加群与Xa因子抑制剂治疗期间金黄色葡萄球菌菌血症(SAB)发生率。中位随访2.0年,达比加群组SAB粗发生率为22.8/10 000人年,Xa因子抑制剂组为33.8/10 000人年;
要点
- 达比加群治疗与房颤患者SAB发生率显著低于Xa因子抑制剂相关。
- 达比加群组SAB粗发生率为22.8/10 000人年,Xa因子抑制剂组为33.8/10 000人年。
核心结论
- 达比加群治疗与显著更低的SAB发生率相关,相比Xa因子抑制剂。
研究设计与样本
- 观察性队列研究,纳入丹麦全国登记系统中2011年8月至2017年12月启动直接口服抗凝药的112 537例房颤患者。
主要发现
- 中位随访2.0年,达比加群组186例、Xa因子抑制剂组356例因SAB入院。
- 达比加群组SAB粗发生率为22.8/10 000人年(95%CI 19.7-26.3),Xa因子抑制剂组为33.8/10 000人年(95%CI 30.5-37.6)。
临床怎么用
- 对于房颤患者选择直接口服抗凝药时,达比加群可能附带降低SAB风险的潜在获益。
局限性
- 为观察性研究,可能存在残余混杂,不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment with dabigatran, an oral direct thrombin inhibitor, reduces the virulence of Staphylococcus aureus in in vitro and in vivo models. However, it remains to be determined whether dabigatran reduces the risk of S. aureus infections in humans. We investigated the incidence rate of S. aureus bacteremia (SAB) in patients with atrial fibrillation treated with the direct thrombin inhibitor dabigatran compared with patients treated with the factor Xa-inhibitors rivaroxaban, apixaban, and edoxaban. METHODS: In this observational cohort study, 112 537 patients with atrial fibrillation who initiated treatment with direct oral anticoagulants (August 2011-December 2017) were identified from Danish nationwide registries. The incidence rates of SAB in patients treated with dabigatran versus patients treated with the factor Xa-inhibitors were examined by multivariable Cox regression accounting for time-dynamic changes in exposure status during follow-up. RESULTS: A total of 112 537 patients were included. During a median follow-up of 2.0 years, 186 patients in the dabigatran group and 356 patients in the factor Xa-inhibitor group were admitted with SAB. The crude incidence rate of SAB was lower in the dabigatran group compared with the factor Xa-inhibitor group (22.8 [95% confidence interval [CI], 19.7-26.3] and 33.8 [95% CI, 30.5-37.6] events per 10 000 person-years, respectively). In adjusted analyses, dabigatran was associated with a significantly lower incidence rate of SAB compared with factor Xa-inhibitors (incidence rate ratio, .76; 95% CI, .63-.93). CONCLUSIONS: Treatment with dabigatran was associated with a significantly lower incidence rate of SAB compared with treatment with factor Xa-inhibitors.
引用
- Butt JH, Fosbøl EL, Verhamme P, et al. Dabigatran and the Risk of Staphylococcus aureus Bacteremia: A Nationwide Cohort Study. Clin Infect Dis. 2021. PMID: 32478836. doi:10.1093/cid/ciaa661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。